TG Therapeutics (NASDAQ:TGTX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

TG Therapeutics (NASDAQ:TGTX) issued its quarterly earnings results on Monday. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01), Briefing.com reports. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same period in the prior year, the business earned $0.73 EPS. The business’s revenue for the quarter was down 49.4% on a year-over-year basis.

TG Therapeutics Trading Up 7.0 %

Shares of NASDAQ:TGTX traded up $1.81 during mid-day trading on Wednesday, reaching $27.67. The stock had a trading volume of 989,470 shares, compared to its average volume of 3,636,302. The firm has a 50 day simple moving average of $23.57 and a two-hundred day simple moving average of $20.26. TG Therapeutics has a twelve month low of $9.81 and a twelve month high of $27.67. The firm has a market cap of $4.28 billion, a PE ratio of -258.60 and a beta of 2.19. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58.

Wall Street Analyst Weigh In

TGTX has been the topic of a number of recent research reports. HC Wainwright lifted their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday. B. Riley upped their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.